Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that belongs to the Coronaviridae family. SARS-CoV-2 is an enveloped spherical-shaped virus. The ribonucleic acid (RNA) is oriented in a 5’-3’direction which makes it a positive sense RNA virus, and the RNA can be rea...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine research 2021-06, Vol.13 (6), p.317-325 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 325 |
---|---|
container_issue | 6 |
container_start_page | 317 |
container_title | Journal of clinical medicine research |
container_volume | 13 |
creator | Vasireddy, Deepa Vanaparthy, Rachana Mohan, Gisha Malayala, Srikrishna Varun Atluri, Paavani |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that belongs to the Coronaviridae family. SARS-CoV-2 is an enveloped spherical-shaped virus. The ribonucleic acid (RNA) is oriented in a 5’-3’direction which makes it a positive sense RNA virus, and the RNA can be read directly as a messenger RNA. The nonstructural protein 14 (nsp14) has proofreading activity which allows the rate of mutations to stay low. A change in the genetic sequence is called a mutation. Genomes that differ from each other in genetic sequence are called variants. Variants are the result of mutations but differ from each other by one or more mutations. When a phenotypic difference is demonstrated among the variants, they are called strains. Viruses constantly change in two different ways, antigenic drift and antigenic shift. SARS-CoV-2 genome is also prone to various mutations that led to antigenic drift resulting in escape from immune recognition. The Center of Disease Control and Prevention (CDC) updates the variant strains in the different classes. The classes are variant of interest, variant of concern and variant of high consequence. The current variants included in the variant of interest by the USA are: B.1.526, B.1.525, and P.2; and those included in the variant of concern by the USA are B.1.1.7, P.1, B.1.351, B.1.427, and B.1.429. The double and triple mutant variants first reported in India have resulted in a massive increase in the number of cases. Emerging variants not only result in increased transmissibility, morbidity and mortality, but also have the ability to evade detection by existing or currently available diagnostic tests, which can potentially delay the diagnosis and treatment, exhibit decreased susceptibility to treatment including antivirals, monoclonal antibodies and convalescent plasma, possess the ability to cause reinfection in previously infected and recovered individuals, and vaccine breakthrough cases in fully vaccinated individuals. Hence, continuation of precautionary measures, genomic surveillance and vaccination plays an important role in the prevention of spread, early identification of variants, prevention of mutations and viral replication, respectively. |
doi_str_mv | 10.14740/jocmr4518 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8256910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552983863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-eff5fe27acb54ca350cd300df71f7dfca6380c7d5a4728c8b37a470c840eeec03</originalsourceid><addsrcrecordid>eNpVUV1LwzAUDaK4MffiL8ijCNWkadrUB0Xm1OFg4McEX0J2m9iMrplNu7F_b3Vj6H25h3vPPefCQeiUkgsaJRG5nDtYVBGn4gB1aUpFwAilh3tMWAf1vZ-Tthijgohj1GFRGCeCpV308axXVq-xM3gwmY7uApriqaqsKmuPVZn9nQLYUuOhMRYUbK7we65qXOcaDwpbWmhv8EvumiLDT6Vb35ygI6MKr_u73kNv98PXwWMwnjyMBrfjABjndaCN4UaHiYIZj0AxTiBr385MQk2SGVAxEwSSjKsoCQWIGUtaREBERGsNhPXQ9VZ32cwWOgNd1pUq5LKyC1VtpFNW_t-UNpefbiVFyOOU_gic7QQq99VoX8uF9aCLQpXaNV6GnIepYCJmLfV8S4XKeV9ps7ehRP7mIfd5sG8mmXv7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552983863</pqid></control><display><type>article</type><title>Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Vasireddy, Deepa ; Vanaparthy, Rachana ; Mohan, Gisha ; Malayala, Srikrishna Varun ; Atluri, Paavani</creator><creatorcontrib>Vasireddy, Deepa ; Vanaparthy, Rachana ; Mohan, Gisha ; Malayala, Srikrishna Varun ; Atluri, Paavani</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that belongs to the Coronaviridae family. SARS-CoV-2 is an enveloped spherical-shaped virus. The ribonucleic acid (RNA) is oriented in a 5’-3’direction which makes it a positive sense RNA virus, and the RNA can be read directly as a messenger RNA. The nonstructural protein 14 (nsp14) has proofreading activity which allows the rate of mutations to stay low. A change in the genetic sequence is called a mutation. Genomes that differ from each other in genetic sequence are called variants. Variants are the result of mutations but differ from each other by one or more mutations. When a phenotypic difference is demonstrated among the variants, they are called strains. Viruses constantly change in two different ways, antigenic drift and antigenic shift. SARS-CoV-2 genome is also prone to various mutations that led to antigenic drift resulting in escape from immune recognition. The Center of Disease Control and Prevention (CDC) updates the variant strains in the different classes. The classes are variant of interest, variant of concern and variant of high consequence. The current variants included in the variant of interest by the USA are: B.1.526, B.1.525, and P.2; and those included in the variant of concern by the USA are B.1.1.7, P.1, B.1.351, B.1.427, and B.1.429. The double and triple mutant variants first reported in India have resulted in a massive increase in the number of cases. Emerging variants not only result in increased transmissibility, morbidity and mortality, but also have the ability to evade detection by existing or currently available diagnostic tests, which can potentially delay the diagnosis and treatment, exhibit decreased susceptibility to treatment including antivirals, monoclonal antibodies and convalescent plasma, possess the ability to cause reinfection in previously infected and recovered individuals, and vaccine breakthrough cases in fully vaccinated individuals. Hence, continuation of precautionary measures, genomic surveillance and vaccination plays an important role in the prevention of spread, early identification of variants, prevention of mutations and viral replication, respectively.</description><identifier>ISSN: 1918-3003</identifier><identifier>EISSN: 1918-3011</identifier><identifier>DOI: 10.14740/jocmr4518</identifier><identifier>PMID: 34267839</identifier><language>eng</language><publisher>Elmer Press</publisher><subject>Review</subject><ispartof>Journal of clinical medicine research, 2021-06, Vol.13 (6), p.317-325</ispartof><rights>Copyright 2021, Vasireddy et al. 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-eff5fe27acb54ca350cd300df71f7dfca6380c7d5a4728c8b37a470c840eeec03</citedby><orcidid>0000-0002-5224-4029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256910/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256910/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Vasireddy, Deepa</creatorcontrib><creatorcontrib>Vanaparthy, Rachana</creatorcontrib><creatorcontrib>Mohan, Gisha</creatorcontrib><creatorcontrib>Malayala, Srikrishna Varun</creatorcontrib><creatorcontrib>Atluri, Paavani</creatorcontrib><title>Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?</title><title>Journal of clinical medicine research</title><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that belongs to the Coronaviridae family. SARS-CoV-2 is an enveloped spherical-shaped virus. The ribonucleic acid (RNA) is oriented in a 5’-3’direction which makes it a positive sense RNA virus, and the RNA can be read directly as a messenger RNA. The nonstructural protein 14 (nsp14) has proofreading activity which allows the rate of mutations to stay low. A change in the genetic sequence is called a mutation. Genomes that differ from each other in genetic sequence are called variants. Variants are the result of mutations but differ from each other by one or more mutations. When a phenotypic difference is demonstrated among the variants, they are called strains. Viruses constantly change in two different ways, antigenic drift and antigenic shift. SARS-CoV-2 genome is also prone to various mutations that led to antigenic drift resulting in escape from immune recognition. The Center of Disease Control and Prevention (CDC) updates the variant strains in the different classes. The classes are variant of interest, variant of concern and variant of high consequence. The current variants included in the variant of interest by the USA are: B.1.526, B.1.525, and P.2; and those included in the variant of concern by the USA are B.1.1.7, P.1, B.1.351, B.1.427, and B.1.429. The double and triple mutant variants first reported in India have resulted in a massive increase in the number of cases. Emerging variants not only result in increased transmissibility, morbidity and mortality, but also have the ability to evade detection by existing or currently available diagnostic tests, which can potentially delay the diagnosis and treatment, exhibit decreased susceptibility to treatment including antivirals, monoclonal antibodies and convalescent plasma, possess the ability to cause reinfection in previously infected and recovered individuals, and vaccine breakthrough cases in fully vaccinated individuals. Hence, continuation of precautionary measures, genomic surveillance and vaccination plays an important role in the prevention of spread, early identification of variants, prevention of mutations and viral replication, respectively.</description><subject>Review</subject><issn>1918-3003</issn><issn>1918-3011</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVUV1LwzAUDaK4MffiL8ijCNWkadrUB0Xm1OFg4McEX0J2m9iMrplNu7F_b3Vj6H25h3vPPefCQeiUkgsaJRG5nDtYVBGn4gB1aUpFwAilh3tMWAf1vZ-Tthijgohj1GFRGCeCpV308axXVq-xM3gwmY7uApriqaqsKmuPVZn9nQLYUuOhMRYUbK7we65qXOcaDwpbWmhv8EvumiLDT6Vb35ygI6MKr_u73kNv98PXwWMwnjyMBrfjABjndaCN4UaHiYIZj0AxTiBr385MQk2SGVAxEwSSjKsoCQWIGUtaREBERGsNhPXQ9VZ32cwWOgNd1pUq5LKyC1VtpFNW_t-UNpefbiVFyOOU_gic7QQq99VoX8uF9aCLQpXaNV6GnIepYCJmLfV8S4XKeV9ps7ehRP7mIfd5sG8mmXv7</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Vasireddy, Deepa</creator><creator>Vanaparthy, Rachana</creator><creator>Mohan, Gisha</creator><creator>Malayala, Srikrishna Varun</creator><creator>Atluri, Paavani</creator><general>Elmer Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5224-4029</orcidid></search><sort><creationdate>202106</creationdate><title>Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?</title><author>Vasireddy, Deepa ; Vanaparthy, Rachana ; Mohan, Gisha ; Malayala, Srikrishna Varun ; Atluri, Paavani</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-eff5fe27acb54ca350cd300df71f7dfca6380c7d5a4728c8b37a470c840eeec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Vasireddy, Deepa</creatorcontrib><creatorcontrib>Vanaparthy, Rachana</creatorcontrib><creatorcontrib>Mohan, Gisha</creatorcontrib><creatorcontrib>Malayala, Srikrishna Varun</creatorcontrib><creatorcontrib>Atluri, Paavani</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vasireddy, Deepa</au><au>Vanaparthy, Rachana</au><au>Mohan, Gisha</au><au>Malayala, Srikrishna Varun</au><au>Atluri, Paavani</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?</atitle><jtitle>Journal of clinical medicine research</jtitle><date>2021-06</date><risdate>2021</risdate><volume>13</volume><issue>6</issue><spage>317</spage><epage>325</epage><pages>317-325</pages><issn>1918-3003</issn><eissn>1918-3011</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that belongs to the Coronaviridae family. SARS-CoV-2 is an enveloped spherical-shaped virus. The ribonucleic acid (RNA) is oriented in a 5’-3’direction which makes it a positive sense RNA virus, and the RNA can be read directly as a messenger RNA. The nonstructural protein 14 (nsp14) has proofreading activity which allows the rate of mutations to stay low. A change in the genetic sequence is called a mutation. Genomes that differ from each other in genetic sequence are called variants. Variants are the result of mutations but differ from each other by one or more mutations. When a phenotypic difference is demonstrated among the variants, they are called strains. Viruses constantly change in two different ways, antigenic drift and antigenic shift. SARS-CoV-2 genome is also prone to various mutations that led to antigenic drift resulting in escape from immune recognition. The Center of Disease Control and Prevention (CDC) updates the variant strains in the different classes. The classes are variant of interest, variant of concern and variant of high consequence. The current variants included in the variant of interest by the USA are: B.1.526, B.1.525, and P.2; and those included in the variant of concern by the USA are B.1.1.7, P.1, B.1.351, B.1.427, and B.1.429. The double and triple mutant variants first reported in India have resulted in a massive increase in the number of cases. Emerging variants not only result in increased transmissibility, morbidity and mortality, but also have the ability to evade detection by existing or currently available diagnostic tests, which can potentially delay the diagnosis and treatment, exhibit decreased susceptibility to treatment including antivirals, monoclonal antibodies and convalescent plasma, possess the ability to cause reinfection in previously infected and recovered individuals, and vaccine breakthrough cases in fully vaccinated individuals. Hence, continuation of precautionary measures, genomic surveillance and vaccination plays an important role in the prevention of spread, early identification of variants, prevention of mutations and viral replication, respectively.</abstract><pub>Elmer Press</pub><pmid>34267839</pmid><doi>10.14740/jocmr4518</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5224-4029</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1918-3003 |
ispartof | Journal of clinical medicine research, 2021-06, Vol.13 (6), p.317-325 |
issn | 1918-3003 1918-3011 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8256910 |
source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Review |
title | Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20COVID-19%20Variants%20and%20COVID-19%20Vaccine%20Efficacy:%20What%20the%20Clinician%20Should%20Know?&rft.jtitle=Journal%20of%20clinical%20medicine%20research&rft.au=Vasireddy,%20Deepa&rft.date=2021-06&rft.volume=13&rft.issue=6&rft.spage=317&rft.epage=325&rft.pages=317-325&rft.issn=1918-3003&rft.eissn=1918-3011&rft_id=info:doi/10.14740/jocmr4518&rft_dat=%3Cproquest_pubme%3E2552983863%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552983863&rft_id=info:pmid/34267839&rfr_iscdi=true |